Membrane Perturbations and Assay Interferences by Ivermectin Explain Its In Vitro SARS-CoV‑2 Antiviral Activities and Lack of Translatability

The antiparasitic drug ivermectin was proposed as a repurposed drug for the treatment of SARS-CoV-2 infection based on in vitro studies, but proved ineffective in high-quality clinical trials. When exploring possible reasons for this disconnect, we found that ivermectin interferes with AlphaScreen a...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας:	Richard T. Eastman (6051881) (author)
Άλλοι συγγραφείς:	Radda Rusinova (4870042) (author), Karl F. Herold (605487) (author), Xi-Ping Huang (391870) (author), Ty Voss (12046550) (author), Alex D. White (7356104) (author), Hugh C. Hemmings (1330833) (author), Olaf S. Andersen (823886) (author), Jayme L. Dahlin (486120) (author)
Έκδοση:	2025
Θέματα:	Biochemistry Medicine Pharmacology Biotechnology Cancer Infectious Diseases Virology Computational Biology Chemical Sciences not elsewhere classified Information Systems not elsewhere classified quality clinical trials perturbing bioactivity early low nanomolar concentrations low micromolar concentrations highlight lessons learned exploring possible reasons 2 viral burden 2 infection based safe antiparasitic drug antiparasitic drug ivermectin ivermectin reduced sars effective antiviral agent antiviral agent repurposed drug drug development pursuing ivermectin ivermectin interferes ivermectin explain proved ineffective perspective </ original justifications membrane perturbations level rationale identifying membrane becomes cytotoxic assay interferences alphascreen assays
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Membrane Perturbations and Assay Interferences by Ivermectin Explain Its In Vitro SARS-CoV‑2 Antiviral Activities and Lack of Translatability

Παρόμοια τεκμήρια